EyePoint Pharmaceuticals (EYPT) Prices 4.03M Share Offering at $13.75/sh

After-Hours Stock Movers 11/16: (CEMI) (LZB) (VREX) Higher; (AVIR) (STNE) (DLB) Lower (more...)

After-Hours Stock Movers:

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) 9.8% LOWER; announced that the strategic collaboration pursuant to which it was jointly developing AT-527 for the treatment of COVID-19 with Roche will be terminating. Upon termination, the rights and licenses granted by Atea to Roche under the strategic collaboration will be returned to Atea, and Atea will have full rights to continue the clinical development and future commercialization of AT-527 worldwide.

Chembio Diagnostics, Inc. (Nasdaq: CEMI)... More

EyePoint Pharmaceuticals (EYPT) Nosedives on Plan to Offer $100M in Common Stock

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) shares were trading more than 6% lower after-hours Tuesday. The company made an announcement, according to which it has commenced an underwritten public offering of $100 million of shares of its common stock, with an intention to grant the... More

EyePoint Pharmaceuticals (EYPT) Announces $100M Stock Offering

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that it has commenced an underwritten public offering of $100.0 million of shares of its common stock. In addition, EyePoint intends to grant the underwriters an option for a period of 30 days to purchase up to an additional $15.0 million of shares of its common stock.

Cowen and Guggenheim Securities are acting as joint book-running managers for the offering. The offering is subject... More

Pre-Open Stock Movers 11/15: (EYPT) (GGPI) (BTB) Higher; (EVGO) (WOOF) (CRWD) Lower (more...)

Pre-Open Stock Movers:

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) 34% HIGHER; announced six-month interim data from the "Durasert® and Vorolanib in Ophthalmology" (DAVIO) Phase 1 clinical trial of EYP-1901, a bioerodible sustained delivery intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment targeting wet age-related macular degeneration (wet AMD). The data are being presented today at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting Retina Subspecialty Day in New... More

EyePoint Pharmaceuticals, Inc. (EYPT) PT Raised to $35 at Cowen

Cowen analyst Ken Cacciatore raised the price target on EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) to $35.00 (from $25.00) while maintaining an Outperform rating.

The analyst commented, "EYP-1901 6-month Phase I wet AMD results demonstrated excellent safety & potential best-in-class efficacy with 73% of patients rescue-free at month 4,... More

EyePoint Pharmaceuticals, Inc. (EYPT) PT Raised to $31 at Cantor Fitzgerald

Cantor Fitzgerald analyst Jennifer Kim raised the price target on EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) to $31.00 (from $22.00) while maintaining an Overweight rating.

The analyst commented, "Following presentation of the Ph1 DAVIO data for EYP-1901 the company's lead pipeline asset in wet age-related macular... More

EyePoint Pharmaceuticals (EYPT) Climbs 55% After Positive Interim Safety and Efficacy Data from Phase 1 DAVIO Trial of EYP-1901

EyePoint Pharmaceuticals (NASDAQ: EYPT) Climbs 55% After Positive Interim Safety and Efficacy Data from Phase 1 DAVIO Trial of EYP-1901

EyePoint Pharmaceuticals, Inc. (EYPT) PT Raised to $24 at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju raised the price target on EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) to $24.00 (from $15.00) while maintaining a Buy rating.

The analyst commented, "On November 13, EyePoint Pharmaceuticals announced six-month interim data from the Phase 1 DAVIO trial of EYP-1901 in wet age-related macular degeneration (AMD) in a presentation at the American Academy of... More

EyePoint Pharmaceuticals (EYPT) Announces Positive Interim Safety and Efficacy Data from Phase 1 DAVIO Trial of EYP-1901

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced six-month interim data from the "Durasert® and Vorolanib in Ophthalmology" (DAVIO) Phase 1 clinical trial of EYP-1901, a bioerodible sustained delivery intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment targeting wet age-related macular degeneration (wet AMD). The data are being presented today at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting Retina Subspecialty Day in New Orleans by David S. Boyer, M.D., Senior Partner at Retina-Vitreous Associates Medical Group and... More